CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: July 9, 2008
Result type: Reports
Project Number: S0142
Product Line: Common Drug Review

Generic Name: Ambrisentan

Brand Name: Volibris

Manufacturer: GlaxoSmithKline Inc.

Indications: Pulmonary arterial hypertension (WHO class II and III)

Submission Type: New

Project Status: Complete

Date Recommendation Issued: December 17, 2008

Recommendation Type: List with clinical criteria and/or conditions